Cancer Family
Neck Neoplasm
CI-CAN-00000283Explore in graph →
Non-malignant634 active trials11 approved drugs67 evidence items
- NCIt
- C3260
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000283Explore in graph →
Clinical trials
2,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT04444869 | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer(ENID) | unknown | Phase 2 | 28 | University of Missouri-ColumbiaOTHER | 1 | May 17, 2024 |
| NCT06364826 | Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma | unknown | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06362694 | Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy | unknown | Phase 2 | 10 | Saint Petersburg State University, RussiaOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04830267 | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC | unknown | Phase 2 | 39 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06259721 | Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05011227 | Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05860335 | Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05385926 | Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 34 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05675605 | A Study of TY-1091 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 248 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03708822 | Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04398524 | A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC | unknown | Phase 2 | 65 | ISA PharmaceuticalsINDUSTRY | 9 | Jan 16, 2024 | clinicaltrials |
| NCT03669718 | A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | unknown | Phase 2 | 194 | ISA PharmaceuticalsINDUSTRY | 13 | Dec 29, 2023 | clinicaltrials |
| NCT06156878 | PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06156891 | PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC | unknown | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06146985 | Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer | unknown | Phase 2 | 67 | Ruijin HospitalOTHER | 0 | Nov 28, 2023 | clinicaltrials |
| NCT05576272 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 460 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05182931 | A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)(I-FIRST) | unknown | Phase 2 | 80 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04277858 | Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.(NECTORS) | unknown | Phase 2 | 60 | Nader SadeghiOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05626829 | Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | unknown | Phase 2 | 18 | Jian GuanOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06051747 | Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea) | unknown | Phase 1 / Phase 2 | 1 | Ja Seong Bae, MD, phDOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT05520814 | PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial | unknown | Phase 2 | 50 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05102292 | The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation | unknown | Phase 1 / Phase 2 | 25 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04156698 | Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma | unknown | Phase 2 | 51 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05981157 | Anrotinib and Tirelizumab in First-line Treatment of RM-NPC | unknown | Phase 2 | 27 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT03925090 | Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04619316 | Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition(ERRITI) | unknown | Phase 2 | 70 | University Hospital, EssenOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913414 | Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 120 | Sun Yat-sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04072107 | EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)(EP-STAR) | unknown | Phase 2 | 110 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04221516 | Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 52 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05898256 | Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Guangxi Medical UniversityOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT04586088 | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | unknown | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05229315 | PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma | unknown | Phase 2 | 45 | XIANG YANQUNOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05790200 | Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05097209 | Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 200 | Wei JiangOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT04870905 | Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05724355 | CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05549466 | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 84 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04405622 | Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | unknown | Phase 2 | 21 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05659186 | PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer | unknown | Phase 2 | 20 | West China HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05551767 | Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer | unknown | Phase 2 | 120 | City Clinical Oncology Hospital No 1OTHER_GOV | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05448885 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT04398056 | Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05431764 | Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05420597 | Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma | unknown | Phase 2 | 61 | Fudan UniversityOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05417139 | Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study | unknown | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04978012 | Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy | unknown | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
Data updated 22 days agoSource updated May 21, 2024source: clinicaltrials